The University of Colorado and Pfizer, Inc. have formed a new partnership to accelerate the translation of biomedical research into effective drug targets and therapies for patients. The agreement funds research projects and postdoctoral fellowships in the biosciences. The collaboration between the two organizations is designed to reduce the time and cost to translate biomedical research into new medications and therapies.
Anticipated project funding from this program will average $200,000 to $250,000 per year, with an expected range from $50,000 to $500,000 per year for approximately two years. Final numbers are dependent on the fit between the submitted proposals with Pfizer’s research interests. The agreement was set up through the newly established Office of Industry Collaboration at CU-Boulder.
Pfizer is looking for academic researchers who are focused on new approaches to cancer diagnoses; on tools and drugs for cardiovascular, neurodegenerative and neuropsychiatric diseases; and methods for evaluating the effectiveness of drugs. Because the agreement is flexible, researchers focused on other biomedical areas are also encouraged to submit a concept.